%20(1).webp)
What Causes High Blood Pressure? Vascular Damage, Metabolism and Peptide Repair Targets
Kelden Peptide Sciences Canada · Understanding hypertension
High blood pressure develops when the circulation needs more force to move blood around the body. Blood vessels may stay too tight, artery walls may become less flexible, or the kidneys may hold on to too much salt and water. Often, several of these changes happen together.
That makes two questions worth asking: What is keeping the pressure high? And what is happening to the tissues exposed to that pressure? This guide explains both, then examines where thymosin beta-4, SS-31, MOTS-c and BPC-157 could fit into repair biology.
The central distinction: Lowering blood pressure reduces the load on the circulation. Protecting the endothelium, heart and kidneys addresses how tissues cope with that load. An experimental compound can affect tissue damage without substantially changing the pressure reading.
What high blood pressure actually means
Blood pressure is the force blood exerts against artery walls. Arteries carry blood away from the heart. A reading contains two numbers because pressure changes during each heartbeat.
Systolic pressure — the top number: the peak pressure as the heart contracts and pushes blood out.
Diastolic pressure — the bottom number: the pressure remaining between beats while the heart relaxes and fills.
For example, 140/90 mmHg means a systolic pressure of 140 and a diastolic pressure of 90. “mmHg” is simply the measurement unit. Pulse pressure is the difference between the two numbers: 50 in this example.
Hypertension means blood pressure stays elevated over time. One reading after exercise, pain or stress does not establish that pattern. Repeated, properly taken readings or a monitor worn during normal daily life give a clearer picture. Blood-pressure measurement and physiology.
Why does blood pressure become high?
Think of the heart as a pump and the blood vessels as living, adjustable pipes. Unlike household pipes, arteries actively tighten, relax and change their structure.
Average pressure depends largely on heart output × resistance to blood flow. Heart output means how much blood the heart pumps each minute. Resistance means how difficult it is for blood to move through the circulation. This relationship describes average pressure; artery stiffness also strongly affects the systolic peak.
Three changes help explain much of the problem:
Tighter small vessels: the same flow meets more resistance.
Stiffer large arteries: each heartbeat meets a wall that cannot stretch as easily.
Excess retained fluid: the kidneys leave too much sodium and water in the circulation, which can raise pressure.
The nervous system can also make the heart pump harder and tell vessels to remain constricted. Age, inherited traits, body fat, sleep, kidney disease and some medicines can influence these systems. Hypertension can arise from several interacting contributors or from a more specific cause, such as excess aldosterone or narrowing of a kidney artery. How the control systems interact.
A healthy blood vessel versus a hypertensive blood vessel
The lumen is the open space blood flows through. The endothelium is the thin living layer lining that space. Around it, smooth-muscle cells adjust vessel diameter, while elastic material and collagen support the wall.
A healthy vessel can widen when tissues need more blood. In hypertension, small arteries may remain contracted or develop thicker walls around a smaller lumen. Large arteries may become stiff. These changes can reinforce one another, but they do not all occur equally in every person.
A useful distinction: Hypertension does not require a cholesterol blockage. A vessel can have poor relaxation or abnormal stiffness without being plugged by plaque.
The eight major biological drivers of hypertension
These are connected processes, not eight separate diagnoses. Several may be active at once.
1. Endothelial dysfunction and loss of nitric oxide
The endothelium acts like a local traffic controller. One of its main messages is nitric oxide, a short-lived signal that tells surrounding muscle to relax. The enzyme eNOS makes nitric oxide in endothelial cells. An enzyme is a protein that carries out a chemical task.
When the lining becomes dysfunctional, less nitric oxide may be made or survive long enough to work. At the same time, constricting signals can become stronger. Endothelin-1 is a particularly powerful vessel-tightening signal made by endothelial cells. Excess endothelin activity can increase resistance to blood flow.
The practical sequence is simple: less effective nitric oxide + stronger constricting signals → less relaxation → greater resistance → higher pressure. “Endothelial dysfunction” therefore means the lining is regulating blood flow poorly; it does not necessarily mean the cells are dead. Endothelial and hormonal control.
2. An overactive angiotensin–aldosterone system
The renin–angiotensin–aldosterone system, shortened to RAAS, helps the body maintain circulation when blood supply or salt availability falls. Trouble develops when its pressure-raising signals are excessive for the body's needs.
The kidneys release renin, an enzyme that starts a sequence. Renin cuts a circulating precursor called angiotensinogen to form angiotensin I. Another enzyme, ACE, converts it into angiotensin II.
Angiotensinogen —renin→ angiotensin I —ACE→ angiotensin II. Renin is the enzyme starting the chain, not the material being converted into angiotensin.
Angiotensin II tells vessels to tighten. It also stimulates aldosterone, a hormone that tells the kidneys to retain sodium; water tends to follow. Its effects extend beyond pressure: it can increase oxidative stress, inflammatory activity and signals that encourage tissue thickening and scarring.
That is why angiotensin-II experiments are useful for studying both hypertension and organ injury. The Tβ4 study below asks what protects tissues while those signals remain active. Angiotensin-II injury model.
3. Kidney dysfunction and sodium retention
The kidneys are long-term blood-pressure regulators. They constantly adjust how much sodium and water leave the body in urine. When too much is retained, circulating volume can increase and pressure can rise.
Kidney damage can disturb this regulation. Conversely, prolonged high pressure can damage the small vessels and filtering structures inside the kidneys. High pressure → kidney injury → poorer pressure regulation → further pressure elevation is an important feedback loop.
The relationship is explained further in our guide to kidney damage, viable tissue and repair. Kidney injury and sodium handling are not identical problems, but both matter when assessing hypertension. Renal control of blood pressure.
4. Insulin resistance and metabolic dysfunction
Insulin resistance means cells respond less effectively to insulin, the hormone that helps regulate blood glucose. The body may compensate by producing more insulin.
This metabolic pattern often travels with abdominal obesity, abnormal blood fats and inflammation. Higher insulin can stimulate sympathetic nerve activity and sodium retention, while high glucose and metabolic stress can interfere with endothelial function and nitric oxide.
The relationship is not automatic: insulin resistance can exist without hypertension. Kidney compression by surrounding fat, RAAS activation, sleep apnea and other obesity-related signals may be more important drivers in some people. The useful target is the whole metabolic problem, rather than assuming one insulin result explains every high reading. Mechanisms and their limits.
Our article on insulin resistance, inflammation and metabolic plateaus explores related contributors.
5. Oxidative stress and mitochondrial dysfunction
Cells naturally produce reactive oxygen species, chemically reactive molecules used in signaling. Oxidative stress means those reactions exceed the cell's ability to keep them under control. Excess superoxide, one such molecule, can consume nitric oxide and reduce its relaxing effect.
Mitochondria help manage cellular energy and stress responses. Damaged mitochondria can become a source of excessive oxidative activity. This can create a loop: mitochondrial stress damages vessel signaling, and the resulting inflammatory environment further stresses mitochondria.
In a 2025 angiotensin-II mouse study, removing a mitochondrial regulator called cyclophilin D from endothelial cells preserved nitric oxide and vessel relaxation and reduced hypertension. This connects mitochondrial function directly to vascular behavior. It was a genetic experiment, not a trial of SS-31. Primary mitochondrial study.
Endothelial cells obtain much of their energy through glycolysis, a process outside mitochondria. Their mitochondrial health still matters because mitochondria regulate oxidative signals and cell survival. The goal is controlled cell function, not simply “more energy.”
6. Persistent inflammation
Inflammation is part of normal defense and repair. When it stays active, immune cells and chemical messengers can keep injuring the vessel lining, increase oxidative stress and encourage abnormal tissue remodeling.
NF-κB is a cellular switch that turns on groups of inflammatory genes. It helps explain how a short-lived stress response can become a continuing source of injury when repeatedly activated.
Inflammation and pressure can drive each other. This is why a compound that reduces an inflammatory marker still needs to be tested for its effects on vessel function, blood pressure and tissue damage separately. Inflammation and hypertensive organ damage.
7. Arterial stiffness, fibrosis and remodeling
Healthy large arteries stretch as blood enters, then recoil between heartbeats. Fibrosis means excessive collagen and other scar-like supporting material build up in tissue. Remodeling means the tissue changes its structure; that can include wall thickening, altered muscle cells and changes in the balance of elastic material and collagen.
A stiffer artery absorbs less of the surge from each heartbeat. This can raise systolic pressure and widen pulse pressure. Remodeling in small resistance arteries can also reduce the space available for flow.
Relaxing muscle and reversing established scar are different jobs. Both may matter, but a lower reading does not prove collagen deposits have disappeared. Vessel structure and hypertension.
8. Sympathetic nervous-system overactivity
The sympathetic nervous system prepares the body for action. One of its messengers, norepinephrine, can tighten blood vessels and increase heart rate and pumping strength. Kidney nerve signals also influence renin release and sodium retention.
When this system stays overactive, pressure can remain elevated. Sleep apnea, obesity and other biological stressors can contribute; this is not simply a matter of feeling anxious or needing to relax. Nervous-system and kidney regulation.
Why high blood pressure eventually damages organs
The heart must push against the increased load. Over time, its muscle may thicken — cardiac hypertrophy — and become less able to relax normally. Fibrosis can contribute to stiffness and, in some cases, impaired pumping.
In the kidneys, injury can cause protein to leak into urine and reduce filtering or regulatory function. In blood vessels, ongoing stress can impair the lining and promote remodeling. Small vessels in the brain and eyes can also be affected.
Pressure is part of the injury, but tissue resilience also matters. Two individuals or animals with similar pressure can develop different amounts of damage because inflammatory activity, metabolic health and protective pathways differ. Organ injury biology.
The repair strategy: what are we actually trying to fix?
The aim is to identify the processes maintaining the problem, reduce ongoing pressure stress and preserve functioning tissue. The following targets are a framework, not a recommendation to take every compound discussed later.
Endothelial dysfunction
What happens: vessels lose some ability to relax.
Target: improve endothelial health, preserve nitric oxide and reduce excessive constricting signals.
Excess angiotensin-II or aldosterone signaling
What happens: vessels tighten; sodium retention, inflammation and remodeling may increase.
Target: control the relevant RAAS signals and their downstream effects.
Oxidative and mitochondrial stress
What happens: nitric oxide is consumed and cellular function is disrupted.
Target: reduce excessive oxidative activity at its source and protect mitochondrial function.
Persistent inflammation
What happens: immune signaling continues to stress endothelial and organ cells.
Target: address the cause and the inflammatory pathways sustaining injury.
Fibrosis and stiffness
What happens: excess matrix and altered wall structure reduce flexibility.
Target: reduce scar-promoting signals and support appropriate tissue remodeling.
Insulin resistance and excess body fat
What happens: metabolic, kidney, hormonal and vascular stresses overlap.
Target: improve glucose regulation, body composition and metabolic health.
Kidney sodium and water retention
What happens: the circulation retains more volume than it needs.
Target: improve sodium handling, manage fluid balance and investigate kidney or hormonal causes.
Sympathetic overactivity
What happens: excessive nerve signals increase vessel contraction and cardiac output.
Target: address sleep apnea and other drivers of autonomic overactivity.
Potential peptide and regenerative targets for hypertension-related damage
Each candidate below has a proposed job. The evidence ranges from cultured cells and animal experiments to human observational data. These are different levels of evidence, and none of the four core candidates below has an established human treatment protocol for systemic hypertension in the studies reviewed here.
Thymosin beta-4 / TB-500: a vascular and tissue-repair pathway
Potential target: how blood vessels, the heart and kidneys survive and remodel under stress.
Thymosin beta-4, written Tβ4 or TB4, is a naturally occurring 43-amino-acid peptide. It interacts with actin, a protein involved in cell shape and movement, and participates in repair-related biology. Its interest extends beyond a simple instruction to relax an artery.
The hypertension study that matters most
In Kumar and colleagues' 2018 study, normal mice and mice genetically lacking Tβ4 received angiotensin II for six weeks. Their systolic pressure rose by similar amounts, yet the Tβ4-deficient mice developed more injury.
They had greater urine protein loss, more inflammatory-cell accumulation and more collagen in the heart and kidneys. Their hearts showed greater enlargement and poorer function. Average ejection fraction — the proportion of blood expelled from the main pumping chamber per beat — was about 78% in normal Ang-II-treated mice versus 63% in deficient mice.
The finding is about protection despite ongoing hypertension. It supports a role for the body's own Tβ4 in limiting organ damage. Removing a protective molecule is not the same experiment as giving extra peptide, but it identifies a pathway worth targeting.
Endothelial survival, senescence and endothelin-1
In a 2022 diabetic endothelial-cell study, researchers used blood-vessel cells made from reprogrammed cells of two people with type 2 diabetes. These were laboratory-grown cells, not patients receiving hypertension treatment.
At 600 ng/mL in culture, Tβ4 improved cell survival and proliferation — the ability to make more cells — and reduced senescence, a stressed state in which cells stop dividing normally. It reduced endothelin-1 production and increased Akt activity. Akt is a protein that relays survival and growth signals inside cells.
Tβ4 combined with these cells also improved blood-flow recovery in diabetic mice with an injured limb blood supply. However, mitochondrial membrane potential and some other abnormalities did not improve. The result supports selected repair functions, rather than correction of every diabetic-cell defect.
Angiogenesis and vascular repair
Angiogenesis means growth of new blood vessels. Together with cell movement and survival, it may help restore blood supply to injured tissue. The 2026 scoping review identifies these as recurring Tβ4 research themes, including PI3K/Akt/eNOS signaling. PI3K and Akt are intracellular message relays; eNOS produces the nitric oxide signal introduced earlier.
New vessel growth is not identical to restoring normal arterial stiffness. Repair requires the right vascular response in the right tissue, not simply more vessels everywhere.
Tβ4 and Ac-SDKP: a connection to fibrosis
Full-length Tβ4 can provide the starting material for Ac-SDKP, a small four-amino-acid peptide. Kidney experiments identified a two-step processing pathway involving meprin-α and prolyl oligopeptidase. These enzymes cut Tβ4 into smaller pieces that yield Ac-SDKP. How Ac-SDKP is produced.
Full-length Tβ4 → enzyme processing → Ac-SDKP → reduced inflammatory and scar-promoting activity in experimental models.
In rats with kidney-artery-induced hypertension, researchers started Ac-SDKP after cardiac fibrosis was already established. Heart collagen decreased alongside reductions in TGF-β and CTGF. These are signals that encourage cells to produce scar-like supporting material. This was a genuine tissue-remodeling experiment, not just an artery-relaxation assay. Cardiac fibrosis study.
In mice with an obstructed kidney, Ac-SDKP reduced collagen, inflammatory cells and scar-producing cells. Tβ4's own effects depended on timing and processing: blocking its breakdown could worsen fibrosis, whereas Tβ4 alone reduced later fibrosis in that model. The pathway is promising, but it is not a universal “anti-scar” switch. Renal fibrosis study.
What pulmonary-hypertension research adds
Pulmonary hypertension affects the circulation between the heart and lungs and places strain on the right side of the heart. It is different from the systemic hypertension measured with an arm cuff.
In a monocrotaline mouse model, Tβ4 treatment reduced right-ventricular pressure and enlargement and reduced fibrotic changes. The investigators examined Notch3, collagen III and CTGF. Notch3 participates in cell-behavior signaling relevant to vascular remodeling; CTGF encourages matrix production. The findings are interesting for abnormal vascular muscle behavior and scarring, but do not establish treatment of ordinary systemic hypertension. Published correction.
TB-500 is related terminology, not a guarantee of the same molecule
The 2026 review mapped 80 studies: 70 investigated Tβ4 directly and only one was classified as direct TB-500 research. Those counts describe its search through March 2026, not every later publication. Most evidence discussed here concerns Tβ4 itself. Scoping review.
A chemical identification study found the seven-amino-acid fragment Ac-LKKTETQ in a TB-500 product. Commercial naming varies. That fragment does not contain Tβ4's N-terminal SDKP sequence, so the full-length Tβ4 → Ac-SDKP mechanism cannot simply be assigned to it.
Our TB-500 page provides product information; the scientific references above identify the materials actually studied. The most compelling hypertension connection is tissue protection and repair biology, not evidence that every TB-500 product functions as a blood-pressure medicine.
SS-31 / elamipretide: mitochondrial protection
Potential target: mitochondrial stress that interferes with cell survival and vascular signaling.
SS-31 interacts with cardiolipin, a specialized fat in the inner mitochondrial membrane. That membrane holds machinery involved in energy production. In rat kidney ischemia experiments — injury caused by interrupted blood supply — SS-31 protected mitochondrial structure and supported recovery of ATP, the cell's usable energy currency. Cardiolipin study.
More directly relevant to vascular function, a study in aged mice found that SS-31 improved nitric-oxide-dependent dilation in the brain's small vessels and their response to local activity. Related endothelial-cell experiments showed lower mitochondrial oxidative stress and better respiration.
The proposed connection is healthier mitochondria → less excess oxidative stress → better preservation of nitric oxide → improved vessel function. The aged-mouse result supports this vascular mechanism; it does not establish a systemic-hypertension cure.
For related material, see SS-31 and our explanation of mitochondrial compounds and cellular energy.
MOTS-c: metabolic regulation and endothelial responsiveness
Potential target: metabolic dysfunction accompanying obesity, poor glucose regulation and vascular stress.
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. It affects AMPK, a cellular energy sensor that helps coordinate fuel use. In the original mouse research, MOTS-c improved insulin sensitivity and protected against high-fat-diet-related obesity and metabolic dysfunction.
A study involving 40 people with recurrent chest pain but no significant structural coronary blockage found lower circulating MOTS-c in those with impaired coronary endothelial function. That was an association, not an injection trial.
In the same paper, pretreating isolated rodent arteries with MOTS-c improved their relaxation response to acetylcholine, a signal used to test the endothelium. MOTS-c did not directly relax the vessels by itself. This distinction points toward improving responsiveness, rather than acting as an immediate vasodilator.
A separate rat vascular-calcification study found less calcium deposition and changes in AMPK and angiotensin-receptor signaling. Calcification means mineral deposition, which differs from collagen fibrosis. These findings add a structural vascular target but do not demonstrate removal of established arterial calcium in people.
This is why MOTS-c is most logically discussed when hypertension overlaps with metabolic problems. Improving that background may reduce vascular stress; it does not make every case of hypertension a MOTS-c deficiency.
BPC-157: nitric oxide and vascular repair signaling
Potential target: impaired endothelial relaxation and blood supply to injured tissue.
In isolated rat arteries, BPC-157 caused concentration-dependent relaxation that relied substantially on an intact endothelium and nitric oxide. Cell experiments connected the response to Src, caveolin-1 and eNOS. In plain language, BPC-157 influenced proteins controlling the endothelial nitric-oxide machinery.
In a separate vascular-growth study, BPC-157 increased endothelial tube formation and improved blood-flow recovery in rats with hindlimb ischemia. The investigators linked these effects to VEGFR2, a receptor involved in vessel-growth signaling, followed by Akt/eNOS activity.
These are concrete reasons to study BPC-157 in vascular dysfunction. They show relaxation and repair-related effects in defined experimental settings. Sustained blood-pressure control and reversal of hypertension-related organ injury are additional outcomes that those experiments did not establish.
KPV, glutathione and ubiquinol: narrower supporting roles
KPV — inflammatory signaling. The previous article included KPV. Its strongest cited work here involves intestinal and immune cells and mouse colitis, where it reduced NF-κB/MAP kinase activity and inflammatory signals. That gives KPV an inflammation-related rationale, but its delivery to vascular targets and effects on hypertension require separate evidence. Primary KPV study.
Glutathione and ubiquinol — redox biology. Glutathione helps cells handle peroxides. Ubiquinol is the reduced form of coenzyme Q10, involved in mitochondrial electron transfer and antioxidant chemistry. Their roles explain why they arise in discussions of oxidative stress. They do not establish that a combined supplement or injection schedule repairs hypertensive arteries. Glutathione biology and CoQ10 biology.
Nutrient support should address an actual dietary or physiological need. More antioxidants, minerals or peptides do not automatically produce more repair.
Established treatments target the same systems
The biological framework also explains why established hypertension care uses different approaches:
ACE inhibitors and angiotensin-receptor blockers: reduce angiotensin-II production or its action at the main pressure-raising receptor.
Aldosterone-receptor blockers: reduce aldosterone's effects on sodium handling and tissue signaling when appropriate.
Calcium-channel blockers: reduce contraction of arterial smooth muscle, helping vessels widen.
Diuretics: help remove sodium and water, reducing excess circulating volume.
Weight reduction and improved metabolic health: reduce several contributors, including kidney, hormonal and sleep-related stress.
Regular exercise: supports vascular function, fitness and metabolic regulation.
Sleep-apnea treatment: addresses repeated breathing interruptions and associated sympathetic activation.
Dietary sodium reduction and appropriate potassium intake: influence kidney sodium handling and pressure regulation. Potassium choices depend on kidney function and medicines; supplementation is not automatically appropriate.
These approaches can complement each other because they address different parts of the system. In the DASH-Sodium randomized trial, the low-sodium DASH diet produced a mean systolic pressure 11.5 mmHg lower than the high-sodium control diet among participants with hypertension. That is measured human blood-pressure evidence, separate from peptide repair experiments. Treatment mechanisms.
How different targets could fit together
A coordinated approach asks what remains dysfunctional after pressure control: persistent metabolic stress, poor endothelial responsiveness, organ injury or abnormal remodeling. Different interventions may address different problems, but a proposed combination still needs to show that its components work together.
An instructive example is a 2025 angiotensin-II mouse study of Ac-SDKP and eplerenone. Treatments improved cardiac function and reduced collagen accumulation and inflammatory-cell infiltration even though systolic pressure remained elevated. The combination provided additional cardiac benefit; the authors described it as additive, not synergistic.
That supports testing complementary targets. It does not validate a stack of TB-500, SS-31, MOTS-c and BPC-157. Nor does tissue protection remove the need to control damaging pressure.
The practical research map is: pressure and volume control + correction of metabolic or sleep-related drivers + investigation of specific repair pathways. Each part should have its own measurable outcome.
What determines whether hypertension can improve?
Blood pressure can improve substantially when its drivers are addressed. How far it improves depends on the cause, duration, kidney function, artery stiffness, body composition, sleep and the amount of established structural injury.
Some changes, such as excessive contraction, may respond relatively quickly. Recovering endothelial function or reducing abnormal remodeling can take longer. Dense scar and lost tissue are more difficult to reverse than stressed but surviving cells.
Control, remission and repair are different outcomes. Normal readings during treatment show control. Sustained normal readings without treatment are a different outcome. Evidence of repair requires measurements beyond the cuff. Treatment changes should be based on repeated readings and clinical assessment, not an assumption that a repair peptide has replaced its role.
Repeated home or ambulatory readings: is pressure consistently better?
Kidney function and urine albumin: is kidney function stable, and is protein leakage improving?
Heart imaging, when indicated: are chamber size, wall thickness and function changing?
Specialist vascular measurements: are arterial stiffness or endothelial responses improving?
Research tissue and molecular tests: are fibrosis, inflammation and the intended pathway changing?
Product analysis answers another question. Our guide to purity, sterility and endotoxin testing explains those distinctions; laboratory reports describe analytical results. A product-quality result is not evidence that a compound treats hypertension.
Frequently asked questions
What causes high blood pressure?
Blood pressure can rise because small vessels stay too tight, large arteries become stiff, the kidneys retain too much sodium and water, or hormonal and nervous-system signals remain overactive. These contributors often overlap with metabolic dysfunction and inflammation.
Can endothelial dysfunction improve?
Yes. Endothelial function can improve when the causes of dysfunction are addressed. Better vessel relaxation does not necessarily mean established fibrosis or calcification has disappeared.
Does thymosin beta-4 lower blood pressure or protect organs?
The key angiotensin-II deficiency study showed worse heart and kidney damage in mice lacking Tβ4 despite similar pressure increases. That makes organ protection a central finding. It does not establish a human blood-pressure-lowering protocol.
Are TB-500 and thymosin beta-4 interchangeable?
No. Most studies discussed here investigated full-length Tβ4. TB-500 naming varies, and some research identified a shorter fragment. The exact molecule matters, especially for the pathway that produces Ac-SDKP.
Why discuss SS-31 and MOTS-c in hypertension?
SS-31 is relevant to mitochondrial stress and endothelial function. MOTS-c is relevant to metabolic regulation and vascular responsiveness. Their experimental findings identify possible targets; they are not interchangeable treatments.
Can BPC-157 repair blood vessels?
BPC-157 improved vascular growth and blood-flow recovery in a rat injury model and affected nitric-oxide-dependent relaxation in isolated arteries. These are specific repair-related findings, not proof of reversal of human hypertension.
Key takeaways
Hypertension is often several systems becoming dysfunctional together. Pressure, fluid volume, vessel relaxation and tissue structure all matter.
Nitric oxide helps arteries relax. Endothelial injury and oxidative stress can weaken that signal.
Tβ4 is particularly interesting for tissue protection. Its hypertension research separates organ injury from the pressure reading itself.
Each peptide has a different proposed target. SS-31 focuses on mitochondrial biology; MOTS-c on metabolic regulation and endothelial responsiveness; BPC-157 on vascular signaling and repair.
Protecting tissue and reducing pressure should be evaluated together. A convincing repair strategy measures both.
Scientific references
The links throughout the article lead to the relevant studies. Primary experiments are distinguished from reviews below. No animal dose has been converted into a human recommendation.
Oparil et al. Hypertension. Nature Reviews Disease Primers, 2018. Physiology and clinical-management review.
Navar. Physiology: Hemodynamics, endothelial function, renin-angiotensin-aldosterone system, sympathetic nervous system. 2014. Physiology review.
Hall et al. Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. 2020. Mechanistic review, including contradictory findings.
McMaster et al. Inflammation, immunity, and hypertensive end-organ damage. 2015. Review.
Depletion of Mitochondrial Cyclophilin D in Endothelial and Smooth Muscle Cells Attenuates Vascular Dysfunction and Hypertension. 2025. Primary mouse research.
Kumar et al. Thymosin β4 Deficiency Exacerbates Renal and Cardiac Injury in Angiotensin-II-Induced Hypertension. 2018. Primary mouse research.
Su et al. Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells. 2022. Patient-derived cell and diabetic-mouse experiments.
Thymosin Beta 4 Protects Mice From Monocrotaline-Induced Pulmonary Hypertension and Right Ventricular Hypertrophy. 2014. Primary mouse and cell research; 2015 correction.
The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase. 2016. Enzyme and animal experiments.
Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. 2003. Primary rat research.
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis. 2013. Primary mouse research showing context-dependent effects.
Ac-SDKP and eplerenone confer additive cardioprotection against angiotensin II-induced cardiac injury in C57BL/6J mice. 2025. Primary combination experiment.
Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences, 2026;16:6202. Review mapping 80 studies.
Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. 2012. Primary chemical identification.
The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. 2013. Primary mechanistic and rat research.
Treatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice. 2018. Primary mouse and cell research.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. 2015. Primary mechanistic and mouse research.
Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. 2018. Human observational and isolated-artery study.
Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via AMPK Signaling. 2020. Primary rat research.
Modulatory effects of BPC 157 on vasomotor tone and the activation of Src–Caveolin-1–eNOS. 2020. Primary isolated-artery and cell experiments.
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. 2017. Primary vascular-growth and injury experiments.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. 2008. Primary cell and mouse-colitis experiments.
Glutathione metabolism and its implications for health. 2004. Biochemical review.
Clinical applications of coenzyme Q10. 2014. Biochemical review.
Sacks et al. Effects on blood pressure of reduced dietary sodium and the DASH diet. 2001. Randomized human trial.
